NCT04319887

Brief Summary

The purpose of this study is to evaluate neurophysiological measures and clinical outcomes of the Evoke System to treat trunk and/or limb pain in a real-world population.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable chronic-pain

Timeline
Completed

Started Oct 2020

Longer than P75 for not_applicable chronic-pain

Geographic Reach
1 country

22 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 17, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 24, 2020

Completed
7 months until next milestone

Study Start

First participant enrolled

October 29, 2020

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 28, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 28, 2023

Completed
1 year until next milestone

Results Posted

Study results publicly available

December 31, 2024

Completed
Last Updated

December 31, 2024

Status Verified

December 1, 2024

Enrollment Period

3.2 years

First QC Date

March 17, 2020

Results QC Date

November 7, 2024

Last Update Submit

December 9, 2024

Conditions

Keywords

Chronic PainBack PainLeg PainPainNeurologic ManifestationsNervous System DiseasesSigns and SymptomsSCSClosed Loop

Outcome Measures

Primary Outcomes (1)

  • Evoked Compound Action Potentials (ECAPs) as Measured by the Evoke SCS System

    Dose ratio is determined by the estimated current (mA) at the median ECAP level divided by the current (mA) at the ECAP threshold. The dose ratio allows for both the individualization of a patient's neural dose and comparison across patients, using their ECAP threshold and unique dose response. This metric normalizes for distance between the electrode and the spinal cord and the distances between the stimulation and recording electrodes. The dose ratio reflects the amount of dorsal column activation elicited by stimulation with respect to threshold levels. For example, if the dose is at ECAP threshold, this value will be 1. If the dose is 30% higher than ECAP threshold, this value will be 1.3.

    12-months post-implant

Other Outcomes (6)

  • Change in Pain

    end of trial period; 1-, 3-, 6-, 12-, 18-, and 24-months post-implant

  • Change in PROMIS-29

    end of trial period; 1-, 3-, 6-, 12-, 18-, and 24-months post-implant

  • Change in PROMIS-10 Global

    end of trial period; 1-, 3-, 6-, 12-, 18-, and 24-months post-implant

  • +3 more other outcomes

Study Arms (1)

ECAP-controlled, closed-loop SCS

EXPERIMENTAL

Spinal cord stimulation that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude

Device: Evoke Spinal Cord Stimulation (SCS) System

Interventions

A spinal cord stimulation system that measures and records evoked compound action potentials (ECAPs) and automatically adjusts the stimulation current to maintain a consistent ECAP amplitude

ECAP-controlled, closed-loop SCS

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject has chronic intractable pain of the trunk and/or limbs.
  • Subject is willing and capable of giving informed consent and able to comply with study-related requirements, procedures, and visits.

You may not qualify if:

  • Subject is unable to operate the system.
  • Subject is an unsuitable surgical candidate.
  • Subject has a condition currently requiring or likely to require the use of diathermy.
  • Subject has another implantable stimulator such as demand type pacemakers or cardioverter defibrillator.
  • Subject is \<18 years old.
  • Subject is pregnant or nursing.
  • Subject is allergic, or has shown hypersensitivity, to any materials of the neurostimulation system which come in contact with the body.
  • Subject is being treated with electroconvulsive therapy (ECT) or transcranial magnetic stimulation (rTMS).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (22)

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

Location

Coastal Pain and Spinal Diagnostics

Carlsbad, California, 92009, United States

Location

Pacific Research Institute

Santa Rosa, California, 95403, United States

Location

The Orthopaedic Institute, PA

Gainesville, Florida, 32607, United States

Location

Alliance Spine and Pain Centers

Atlanta, Georgia, 30326, United States

Location

Southern Pain and Spine

Fayetteville, Georgia, 30214, United States

Location

Axis Spine Center

Hayden Lake, Idaho, 83835, United States

Location

University of Kansas Medical Center Research Institute

Kansas City, Kansas, 66160, United States

Location

Ochsner Clinic

New Orleans, Louisiana, 70121, United States

Location

Interventional Spine and Pain Physicians

Maple Grove, Minnesota, 55369, United States

Location

Nevada Advanced Pain Specialists

Reno, Nevada, 89511, United States

Location

Albany Medical College

Albany, New York, 12208, United States

Location

Duke University

Durham, North Carolina, 27705, United States

Location

University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States

Location

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States

Location

Oregon Health and Science University

Portland, Oregon, 97239, United States

Location

Spinal Diagnostics, PC

Tualatin, Oregon, 97062, United States

Location

Delaware Valley Pain & Spine Institute

Feasterville-Trevose, Pennsylvania, 19053, United States

Location

Center for Interventional Pain and Spine

Lancaster, Pennsylvania, 55419, United States

Location

Sprintz Center for Pain PLLC

Shenandoah, Texas, 77384, United States

Location

Precision Spine Care

Tyler, Texas, 75701, United States

Location

St. Francis Hospital

Charleston, West Virginia, 25301, United States

Location

Related Publications (1)

  • Pope JE, Antony A, Petersen EA, Rosen SM, Sayed D, Hunter CW, Goree JH, Vu CM, Bhandal HS, Shumsky PM, Bromberg TA, Smith GL, Lam CM, Kalia H, Lee JM, Khurram A, Gould I, Karantonis DM, Deer TR. Identifying SCS Trial Responders Immediately After Postoperative Programming with ECAP Dose-Controlled Closed-Loop Therapy. Pain Ther. 2024 Oct;13(5):1173-1185. doi: 10.1007/s40122-024-00631-4. Epub 2024 Jul 9.

MeSH Terms

Conditions

Chronic PainBack PainPainNeurologic ManifestationsNervous System DiseasesSigns and Symptoms

Interventions

Spinal Cord StimulationDrug Delivery Systems

Condition Hierarchy (Ancestors)

Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsPhysical Therapy ModalitiesRehabilitationDrug Therapy

Results Point of Contact

Title
Angela Leitner
Organization
Saluda Medical

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 17, 2020

First Posted

March 24, 2020

Study Start

October 29, 2020

Primary Completion

December 28, 2023

Study Completion

December 28, 2023

Last Updated

December 31, 2024

Results First Posted

December 31, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Locations